Drug Trials News for November 2012

Drug Trials News Archive

New oral drug overcomes resistance in patients with rare sarcoma after failure of standard targeted therapies New oral drug overcomes resistance in patients with rare sarcoma after failure of standard targeted therapies

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

Smart drug improves survival in older patients with acute myeloid leukemia Smart drug improves survival in older patients with acute myeloid leukemia

A new study has found Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 percent less likely to relapse and around 13 percent less likely to die from their disease. The results are from a major phase III Cancer Research UK-funded trial led by Cardiff University.

New medication shows promise as lipid-lowering therapy for rare cholesterol disorder New medication shows promise as lipid-lowering therapy for rare cholesterol disorder

An international effort led by researchers at the Perelman School of Medicine at the University of Pennsylvania has resulted in positive phase 3 clinical trial results for a new medicine to treat patients suffering from a rare and deadly cholesterol disorder.